In Vivo Lung-Targeted
RNA Transfection Kit
Satreda LNP6005
Empowering Next-Generation Lung Research and Therapies
With its combination of precision targeting, high safety, and broad RNA compatibility, the SatredaLNP 6005 kit is a transformative tool for scientists exploring pulmonary disease mechanisms, RNA-based therapeutics, and vaccine delivery. Whether for preclinical studies, drug development, or translational research, this technology offers a scalable, reproducible, and cutting-edge solution that brings lung-targeted RNA delivery into a new era of precision medicine.
A Breakthrough in Lung-Targeted RNA Delivery
The SatredaLNP 6005 represents a major innovation in in vivo RNA delivery, purpose-built for precise and efficient targeting of lung tissue. Developed using Satreda’s next-generation lipid nanoparticle (LNP) technology, LNP6005 integrates advanced targeting ligand design and proprietary lipid formulations to overcome one of the greatest limitations in RNA therapeutics — efficient and selective delivery beyond the liver.
By achieving exceptional organ specificity of up to 94% lung targeting, LNP6005 sets a new benchmark for pulmonary RNA transfection, enabling researchers to explore novel treatment strategies for lung-related diseases with unmatched accuracy and safety.
Broad RNA Compatibility for Versatile Research
LNP6005 is designed to support a wide range of RNA molecules, including siRNA, mRNA, gRNA, and circRNA, making it a highly versatile platform for diverse biomedical applications. From gene silencing and CRISPR gene editing to mRNA vaccine development and protein expression studies, this kit enables researchers to tailor RNA-based therapies and experiments with flexibility and confidence.
High Safety, Ethanol-Free Design
Formulated with biodegradable, non-toxic lipids, LNP6005 ensures excellent biocompatibility and low immunogenicity, even in repeated-dose studies. Its ethanol-free composition eliminates potential irritation, hemolysis, or vascular side effects commonly associated with traditional formulations. The result is a system that achieves high organ specificity with minimal systemic exposure, enabling safer in vivo studies and therapeutic development.
Efficiency, Flexibility, and Ease of Use
As part of Satreda’s in vivo LNP series, LNP6005 is engineered for workflow simplicity and experimental adaptability. Researchers can flexibly employ multiple administration routes — including intravenous, intratracheal, or localized injection — depending on study design. Its ready-to-use formulation allows rapid, efficient RNA encapsulation within just one minute, replacing the 10+ hour encapsulation processes of traditional systems. This efficiency accelerates discovery timelines while maintaining consistent and high-quality results.
Precision Targeting Through Advanced Lipid Engineering
At the core of LNP6005 is Satreda’s modular lipid design and targeting ligand technology, which fine-tunes particle surface properties for precise biodistribution. These optimized LNPs leverage a controlled size, charge, and surface composition to selectively home to lung tissue after systemic administration, while minimizing uptake by off-target organs such as the liver or spleen.
This refined targeting not only enhances transfection efficiency within lung cells but also substantially reduces non-specific expression, ensuring both superior efficacy and improved safety profiles compared to conventional LNP systems.